Antisense approaches to cancer gene therapy
Related Experiment Videos
Abstract:
Recent advances in the use of oligodeoxynucleotide and plasmid-derived RNA as antisense agents of special relevance to cancer gene therapy are summarized with emphasis on agents and systems which have lead to clinical trials and/or regression of established tumors in animal model systems. Transformed cell lines bearing plasmids and viruses designed for the transcription of antisense RNA have the advantage that they can be characterized thoroughly and the effects of antisense RNA on target gene expression and phenotype can be studied easily in vivo. Promising results make the considerable efforts of applying oligodeoxynucleotides in whole animals and in clinical trials more plausible. Conversely, oligodeoxynucleotide experiments which yield promising results in tissue culture can be generalized to the in vivo setting by development of clones of cells bearing plasmid-derived antisense RNA against the same target. Several examples of the concordant results for oligodeoxynucleotide and plasmid-derived antisense RNA against the same target are considered. The importance of examination of antisense effects in syngeneic and immunocompetent hosts is illustrated by studies of insulin-like growth factor and insulin-like growth factor receptor where tumor regression and protection against tumor formation have been observed for particular cell types in defined settings.
Insights
Oligodeoxynucleotides and plasmid-derived RNA show promise as antisense agents for cancer gene therapy. These agents have demonstrated tumor regression in animal models and are advancing to clinical trials.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Antisense agents, including oligodeoxynucleotides and plasmid-derived RNA, are crucial for cancer gene therapy.
- Recent advancements focus on agents and systems progressing to clinical trials or showing tumor regression in animal models.
Purpose of the Study:
- To summarize recent progress in oligodeoxynucleotide and plasmid-derived RNA antisense agents for cancer gene therapy.
- To highlight agents and systems that have advanced to clinical trials or demonstrated efficacy in preclinical models.
Main Methods:
- Utilizing transformed cell lines with plasmids/viruses for antisense RNA transcription for in vivo studies.
- Investigating oligodeoxynucleotide applications in whole animals and clinical trials.
- Comparing results from oligodeoxynucleotide and plasmid-derived antisense RNA targeting the same genes.
- Examining antisense effects in syngeneic and immunocompetent hosts.
Main Results:
- Transformed cell lines facilitate thorough characterization of antisense RNA effects on gene expression and phenotype.
- Promising results from cell culture studies support the in vivo application of oligodeoxynucleotides.
- Concordant results observed for both oligodeoxynucleotide and plasmid-derived antisense RNA against common targets.
- Tumor regression and protection against tumor formation observed in studies of insulin-like growth factor and its receptor.
Conclusions:
- Antisense agents, particularly oligodeoxynucleotides and plasmid-derived RNA, hold significant potential for cancer gene therapy.
- Preclinical successes are paving the way for broader clinical applications.
- In vivo validation in relevant host models is critical for assessing therapeutic efficacy.